Document is current
Any future updates will be listed below
-
Authors
Yarlas, Aaron https://orcid.org/0000-0003-4600-259X
Lovley, Andrew
Brown, Duncan
Vera-Llonch, Montserrat
Khella, Sami
Karam, Chafic
- License Information
-
More Information
Article History
Received: 11 March 2022
Accepted: 9 February 2023
First Online: 17 March 2023
Declarations
:
: The trial protocol was approved by institutional review boards or local ethics committees. The trial was conducted in accordance with Good Clinical Practice guidelines of the International Conference on Harmonisation and the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants included in the study.
: Not applicable.
: At the time of this research, AY was an employee of QualityMetric, which received payment from Ionis Pharmaceuticals Inc., to conduct these analyses and develop this manuscript; AY is currently an employee of and owns stock in Ionis Pharmaceuticals Inc. AL is an employee of QualityMetric. DB and MVL are employees of and own stock in Ionis Pharmaceuticals Inc. SK has received consulting honoraria from Ionis Pharmaceuticals, Akcea Therapeutics, Alnylam, Pfizer, and Eidos. CK has received consulting honoraria from Ionis Pharmaceuticals, Akcea Therapeutics, Argenx, CSL Behring, Alnylam, Biogen, and Sanofi.
